title: Inhibitory effect of somatostatin on the NPY response to insulin-induced hypoglycemia and the role of endogenous opioids.
abstract: The present study was undertaken in order to establish whether somatostatin (SRIH) is able to modify the neuropeptide Y (NPY) response to insulin-induced hypoglycemia during insulin tolerance test (ITT) in man. In addition, the possible involvement of opioid peptides in the mediation of hypoglycemia and/or SRIH action was investigated. Subjects were injected intravenously with 0.15IU/kg insulin alone (control test) or with SRIH (4.1μg/min/90min), naloxone (10mg in an iv bolus) or the combination of the two substances. Plasma NPY concentrations rose significantly during ITT. The NPY response was significantly reduced by the treatment with SRIH. The administration of naloxone did not modify NPY levels whereas when both SRIH and naloxone were given, NPY response to hypoglycemia did not differ from that observed in the control test. These data demonstrate that SRIH inhibits the NPY response to hypoglycemia. Naloxone-sensitive endogenous opiates do not seem to be involved in the control of hypoglycemia-induced NPY release. In contrast, since naloxone reversed the inhibiting effect of SRIH, an involvement of opioid peptides in the SRIH action may be supposed.
authors.affiliation: Department of Internal Medicine and Biomedical Sciences, University of Parma, Parma, Italy. vittorio.coiro@unipr.it
authors.forename: V
authors.initials: V
authors.lastname: Coiro
authors.forename: R
authors.initials: R
authors.lastname: Volpi
authors.forename: A
authors.initials: A
authors.lastname: Stella
authors.forename: F
authors.initials: F
authors.lastname: Maccanelli
authors.forename: A
authors.initials: A
authors.lastname: Araldi
authors.forename: C
authors.initials: C
authors.lastname: Giumelli
authors.forename: M G
authors.initials: MG
authors.lastname: Magotti
authors.forename: S
authors.initials: S
authors.lastname: Cataldo
authors.forename: P
authors.initials: P
authors.lastname: Chiodera
mesh_terms: D000328:Adult; D001786:Blood Glucose; D006400:Hematocrit; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced* / Q000378:metabolism; D007328:Insulin; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009478:Neuropeptide Y / Q000037:antagonists & inhibitors* / Q000097:blood; D018847:Opioid Peptides / Q000502:physiology*; D013004:Somatostatin / Q000494:pharmacology* / Q000502:physiology
chemical_list: D001786:Blood Glucose; D007328:Insulin; D009292:Narcotic Antagonists; D009478:Neuropeptide Y; D018847:Opioid Peptides; D009270:Naloxone; D013004:Somatostatin